MedTrace Logo

The Burden of Acute Respiratory Failure in Chinese ICUs: a National Cohort Study

NCT06213779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4032

Last updated 2026-04-28

No results posted yet for this study

Summary

We aim to prospectively assess the burden, management and therapeutic approaches and outcomes of acute respiratory failure requiring respiratory support, during the winter months in China.

The purpose of this study is to provide new and current data on the disease burden of acute respiratory failure and ARDS. It will answer the following questions:

* The frequency and disease burden of acute respiratory failure in China;
* The incidence of ARDS based on the new global definition within this patient cohort.
* The mortality of ARDS within this cohort, and how does this vary based on ARDS categories and severity.
* The long-term outcomes (1-year mortality and survivor quality of life) of ARDS within this cohort.
* The nature course of ARDS (different stages and severity of ARDS).
* The respiratory support management strategies, such as recruitment maneuvers, prone positioning, ECCO2R, and ECMO.
* The use of drugs during ICU stays, including glucocorticoid, anticoagulant, nitric oxide, sivelestat, Xuebijing, and ulinastatin.
* The economical burden of acute respiratory failure within this patient cohort.
* The impact of occupation, incomes and education levels on the incidence and mortality of ARDS.

Conditions

  • Acute Respiratory Failure
  • Acute Respiratory Distress Syndrome

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-04-30
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06213779 on ClinicalTrials.gov